SCHEMBL6407540

SCHEMBL6407540

C1=CC=C2c3ccccc3SC2C=C1

nearest known ligand 0.30

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TTK P33981 1/20 0.30
MAPK8 P45983 1/20 0.30
MAPK9 P45984 1/20 0.30
MAPK10 P53779 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4324158 0.92 TTK (0.35) TTKMAPK8MAPK9MAPK10
SCHEMBL1385817 0.68
SCHEMBL23431208 0.68
SCHEMBL24286041 0.67 ALOX5 (0.30)
SCHEMBL24541282 0.67 BCHE (0.31)
SCHEMBL7905020 0.64 MAPT (0.31)
SCHEMBL23253993 0.61
SCHEMBL6410680 0.59 KDM4E (0.32)
SCHEMBL12199688 0.59 ALOX5 (0.43)
SCHEMBL16465580 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026042047-A1 COMPOSITIONS AND ARTICLES COMPRISING REVERSIBLE COMPLEXES OF CROSSLINKED CARRAGEENAN JOHNSON & JOHNSON VISION CARE, INC. (US) 2026-02-26 WO claimed
EP-2727919-B1 BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD (CN) 2019-05-08 EP claimed
US-10022362-B2 Anti-allergy benzocycloheptathiophene derivatives FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) 2018-07-17 US claimed
US-20160166563-A1 Anti-Allergy Benzocycloheptathiophene Derivatives FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) 2016-06-16 US claimed
US-9296731-B2 Anti-allergy benzocycloheptathiophene derivatives FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) 2016-03-29 US claimed
US-20140135361-A1 ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) 2014-05-15 US claimed
EP-2727919-A1 BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) 2014-05-07 EP claimed
US-5457099-A Carbostyril derivatives and antiallergic agent SAWAI PHARMACEUTICAL CO., LTD. (JP) 1995-10-10 US claimed
US-4128549-A Precursors of 4-(1-alkyl-4-piperidylidene-4H-benzo[4,5]cyclohepta-[1,2-b]thiophen-10(9H)-ones SANDOZ LTD. (CH) 1978-12-05 US claimed
US-3960894-A 9-Bromo-or chloro-9,10-dihydro-10-dihydro-10-alkoxy-4H-benzo[4,5]cyclo-hepta[1,2-b]thiophen-4-ones SANDOZ LTD. (CH) 1976-06-01 US claimed
WO-2026042047-A1 COMPOSITIONS AND ARTICLES COMPRISING REVERSIBLE COMPLEXES OF CROSSLINKED CARRAGEENAN JOHNSON & JOHNSON VISION CARE, INC. (US) 2026-02-26 WO disclosed
WO-2026042049-A1 DOUBLE NETWORK HYDROGEL AND PREPARATION AND APPLICATION THEREOF JOHNSON & JOHNSON VISION CARE, INC. (US) 2026-02-26 WO disclosed
US-20250288591-A1 TRIMEPRAZINE FOR USE IN TREATING TRIGEMINAL NEURALGIA AND FOR REDUCING PAIN RELATED THERETO UNDAUNTED BIO, INC. (US) 2025-09-18 US disclosed
US-20250134903-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN UNDAUNTED BIO, INC. (US) 2025-05-01 US disclosed
EP-3927428-B1 NORKETOTIFEN FOR USE IN THE TREATMENT OF RESPIRATORY DISORDERS BRIDGE PHARMA INC (US) 2025-03-05 EP disclosed
US-4031225-A ANTIARRHYTHMIA AGENTS SANDOZ LTD. (CH) 1977-06-21 US disclosed
US-4024266-A LUTEINIZING HORMONE INHIBITORS, ANTIDEPRESSANTS SANDOZ LTD. (CH) 1977-05-17 US disclosed
US-3960894-A 9-Bromo-or chloro-9,10-dihydro-10-dihydro-10-alkoxy-4H-benzo[4,5]cyclo-hepta[1,2-b]thiophen-4-ones SANDOZ LTD. (CH) 1976-06-01 US disclosed
US-3960894-A 9-Bromo-or chloro-9,10-dihydro-10-dihydro-10-alkoxy-4H-benzo[4,5]cyclo-hepta[1,2-b]thiophen-4-ones SANDOZ LTD. (CH) 1976-06-01 US disclosed
US-3862156-A 4H-BENZO{8 4,5{9 CYCLOHEPTA{8 1,2-6{9 THIOPHENES SANDOZ AG 1975-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166563-A1 Anti-Allergy Benzocycloheptathiophene Derivatives NR1H4, TST, CYP7A1 TTK 3958/4885MAPK8 2662/4885MAPK9 2400/4885
US-20140135361-A1 ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES TST, HRH1, ABCB11 TTK 3667/4885MAPK8 3418/4885MAPK9 2084/4885
US-10022362-B2 Anti-allergy benzocycloheptathiophene derivatives NR1H4, TST, CYP7A1 TTK 3958/4885MAPK8 2662/4885MAPK9 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.